Affiliation:
1. 1 Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health , Medical University-Pleven , Bulgaria
Abstract
SummaryA patient diagnosed with late-presenting HIV infection [CD4 count 86 cells/mm3, viral load (VL) 95 000 copies RNA/mL], treated with DRV/c 800/150 mg (Rezolsta®) and TDF/FTC 200/245 mg, was hospitalized with ischemic brain stroke, confirmed by CT scan and MRI. Motor functions quickly recovered, but nausea, abdominal heaviness, ascites, and hepatosplenomegaly appeared. Laboratory investigations revealed anaemia, thrombocytopenia, normal transaminases, increased GGT and negative serological tests for HBV and HCV and she was diagnosed with Gastroenterologists diagnosed liver cirrhosis. After 20 days of hospital treatment, the patient recovered from the stroke and ascites but with persisting anaemia and thrombocytopenia. Liver cirrhosis had been confirmed, and relevant treatment had been administered. Six months later, an MRI of the brain revealed an improved image. Follow-up showed stabilized somatic and neurologic status, improved laboratory parameters, stable T-helper count and undetectable viral load (VL). ART regimen continued with Raltegravir 400 mg (Isentress®) 2×1 tablet/24 h, TDF/FTC 200/245 mg 1 tablet/24 h. Three months later, the patient continued her treatment continued abroad. The increased access to precise diagnosis and treatment with improved adherence has transformed the HIV-infection into a manageable chronic health condition, even in complicated cases.
Reference22 articles.
1. UNAIDS. Fact sheet – World AIDS Day 2021. [Internet] Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
2. Samuel K. Getting to 95-95-95: global use of HIV generics would result in large reductions in spending, new infections and deaths. NAM AIDS map 2021 July 9 [Internet] Available from: https://www.aidsmap.com/news/jul-2021/getting-95-95-95-global-use-hiv-generics-would-result-large-reductions-spending-new
3. Heath K, Levi J, Hill A. Reaching UNAIDS 95-95-95 targets worldwide: predicted benefits and treatment costs with generic manufacture. AIDS. 2021;35(2):197-203.
4. Girum T, Wasie A, Worku A. Trend of HIV/AIDS for the last 26 years and predicting achievement of the 90-90-90 HIV prevention targets by 2020 in Ethiopia: a time series analysis. BMC Infect Dis. 2018;18:320.
5. UNAIDS. Global AIDS update 2020. Seizing the moment: tackling entrenched inequalities to end epidemics. 2020. [Internet] Available from: https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf